The 36-month beta value for TLSA is at 0.63. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TLSA is 121.18M, and currently, shorts hold a 0.06% of that float. The average trading volume for TLSA on August 07, 2024 was 207.05K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TLSA) stock’s latest price update
The stock of Tiziana Life Sciences Ltd (NASDAQ: TLSA) has increased by 17.41 when compared to last closing price of 1.09.Despite this, the company has seen a gain of 19.61% in its stock price over the last five trading days. proactiveinvestors.com reported 2024-07-24 that Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares moved higher after the biotechnology firm revealed the US Food and Drug Administration (FDA) has granted Fast Track designation to its intranasal formulation of foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis. The FDA’s Fast Track designation is intended to support the development of and review of drugs that address an unmet medical need.
TLSA’s Market Performance
TLSA’s stock has risen by 19.61% in the past week, with a monthly rise of 57.81% and a quarterly rise of 88.26%. The volatility ratio for the week is 10.57% while the volatility levels for the last 30 days are 8.37% for Tiziana Life Sciences Ltd The simple moving average for the last 20 days is 37.37% for TLSA’s stock, with a simple moving average of 94.06% for the last 200 days.
Analysts’ Opinion of TLSA
Many brokerage firms have already submitted their reports for TLSA stocks, with B. Riley Securities repeating the rating for TLSA by listing it as a “Buy.” The predicted price for TLSA in the upcoming period, according to B. Riley Securities is $8 based on the research report published on December 22, 2020 of the previous year 2020.
TLSA Trading at 41.27% from the 50-Day Moving Average
After a stumble in the market that brought TLSA to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 16.35% of gains for the given period.
Volatility was left at 8.37%, however, over the last 30 days, the volatility rate increased by 10.57%, as shares surge +52.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +58.04% upper at present.
During the last 5 trading sessions, TLSA rose by +19.63%, which changed the moving average for the period of 200-days by +93.94% in comparison to the 20-day moving average, which settled at $0.9536. In addition, Tiziana Life Sciences Ltd saw 128.54% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for TLSA
The total capital return value is set at -2.58.
Based on Tiziana Life Sciences Ltd (TLSA), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -63.55. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -2083.71.
Currently, EBITDA for the company is -15.34 million with net debt to EBITDA at 0.06.
Conclusion
In conclusion, Tiziana Life Sciences Ltd (TLSA) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
